Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Rent the Runway Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Rent the Runway Inc trades at $1.71 (market cap $61.07M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 46.8× Rent the Runway Inc's market cap, and Rent the Runway Inc is more actively traded (80,595 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Rent the Runway Inc for 56 Days on average.
| DYN | RENT | |
|---|---|---|
Market Cap | $2.86B | $61.07M |
Volume | 3,341,579 | 80,595 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $9.39 |
52-Week Low | $14.60 | $1.55 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.18B | $228.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Rent the Runway (RENT) trades at $1.71, down 6.56% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with a gross margin of 74.73%, though net income was -$69.90M. Recent news includes a CEO appointment and multiple law firm investigations into investor claims.
The outlook remains challenging with negative equity and high debt, but improving margins and projected 2026 profitability offer potential. Risks include legal scrutiny and financial leverage, while analyst consensus is cautiously optimistic with 42% buy ratings. Stock performance hinges on execution of turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
